BioSensics Priority Therapeutic Areas

BioSensics wearable sensors and digital health technologies have been used in more than 100 clinical trials and research studies. In over 25 clinical trials, our products have been employed to assess primary and/or secondary endpoints. Moreover, researchers across the globe are utilizing our technologies in many therapeutic areas, leading to the publication of over 200 journal articles to date.

BioSensics not only offers its products and services to pharmaceutical companies and clinical researchers but also conducts its own clinical studies with a primary emphasis on developing digital measurement tools and biomarkers for neurological and neuromuscular disorders.

We are delighted to share our focus on 8 priority therapeutic areas, encompassing two prevalent neurological disorders affecting millions of individuals, along with six rare neurological and neuromuscular disorders that currently lack a cure.

1. Alzheimer's disease

2. Amyotrophic lateral sclerosis (ALS)

3. Hereditary ataxias (including SCA and FA)

4. Huntington's disease

5. Multiple system atrophy

6. Myasthenia gravis

7. Parkinson's disease

8. Progressive supranuclear palsy. 

BioSensics has received nearly $17 million of funding from the National Institutes of Health, and partners with pharmaceutical companies, Centers of Excellence, top research institutions, and patient advocacy groups to support its clinical studies.

The data collected in our studies are accessible within the BioDigit Database, and will be provided to selected partners, clients, and researchers. If you wish to explore possibilities for collaboration and partnership, please schedule a demo.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of its solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consulting services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.